Loading clinical trials...
Loading clinical trials...
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period
Conditions
Interventions
Insulin aspart
NovoLog/NovoRapid
+1 more
Locations
82
United States
Investigational Site Number 8400040
Little Rock, Arkansas, United States
Investigational Site Number 8400012
Concord, California, United States
Investigational Site Number 8400002
Escondido, California, United States
Investigational Site Number 8400030
Fresno, California, United States
Investigational Site Number 8400004
Greenbrae, California, United States
Investigational Site Number 8400014
La Jolla, California, United States
Start Date
August 2, 2017
Primary Completion Date
July 16, 2018
Completion Date
January 12, 2019
Last Updated
March 28, 2022
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions